Arcus Biosciences

Being diagnosed with #stomachcancer felt like a labyrinth, but Melani found her way and her purpose. Now more than 15 years later, she’s lighting a path for others as a mentor with Debbie's Dream Foundation: Curing Stomach Cancer. Honored to showcase #PortrAItsofCancer at #DDFAdvocacyDay2025 this week and connect with the stomach #cancer community gathering in Washington DC to advocate for research, prevention and early detection. Learn more about Melani’s story: https://bit.ly/3QxANg1

We're reporting our fourth-quarter and full-year financial results as well as an update on our clinical-stage pipeline: https://bit.ly/41iuPEC

Today we announced that Arcus will retain the rights to casdatifan, our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer, and shared pricing of $150 million common stock offering. This financing is expected to fund Arcus through the anticipated data readout for PEAK-1, the Phase 3 trial for casdatifan in patients with clear cell renal cell carcinoma who have previously received anti-PD-1 therapy. Read the news here: https://bit.ly/3X2tL6E

Understanding new ways to pursue established cancer targets is essential to improve how we can treat the disease. At ASCO #GU25 this weekend, we presented data from our ARC-20 study evaluating a differentiated investigational HIF-2a inhibitor for the treatment of #kidneycancer. Learn from our Senior Director of Medicinal Chemistry Ken Lawson about how casdatifan works to inhibit cancer cell growth: https://bit.ly/3D3lkkE

New clinical data for casdatifan were presented today in a rapid oral session at the ASCO #GU25 Symposium. These data support the potential for our investigational molecule casdatifan to be a best-in-class HIF-2a inhibitor to treat metastatic #kidneycancer. Read more about the data that was presented: https://bit.ly/4gGo5Gr

This week marked 10 years of the International Day of Women and Girls in Science, a time to celebrate the contributions women have made in STEM, but also to ask, “how can we all do better?” The global average percentage of female STEM researchers is just over 33%, and only 35% of all students in STEM-related fields of study are women (UNESCO). At Arcus, we’re proud to have closed the gender gap with over half of our company – and leadership – being made up of women. “I find science exciting because it gives you the chance to solve real problems and see the impact of your work firsthand,” says Chandni A., an associate scientist in biophysics at Arcus. “If you’re curious, driven, and love a good challenge, there’s a place for you in STEM – and we need more women to take that leap!” A round of applause for all our employees helping to elevate #EveryVoiceInScience! #February11

New clinical data for casdatifan, our HIF-2a inhibitor for the treatment of metastatic #kidneycancer will be presented in a rapid oral session this Saturday at the ASCO #GU25 Symposium. Read more about this news: https://bit.ly/4hNQ08n

We are thrilled to welcome Richard Markus, M.D., Ph.D., to the Arcus team as chief medical officer. He will oversee our clinical development organization and its late-stage portfolio. https://bit.ly/40LlSDV

We are at the forefront of #cancer research with a differentiated portfolio of late-stage programs and potential best-in-class investigational molecules. #JPM25 Learn more about our strategic approach to enabling differentiated combination therapies to treat those living with cancer. https://bit.ly/42dvqtn

Tomorrow afternoon, our CEO Terry Rosen will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. #JPM25 Watch the presentation in-person if you are attending the conference or join the live webcast here: https://bit.ly/42bpUaK